CytImmune Sciences Inc.

https://www.cytimmune.com

CytImmune is a clinical stage nanomedicine company with a core focus on the discovery, development and commercialization of multifunctional, tumor-targeted cancer therapies. Based on a research and development strategy to harness the unique properties of gold nanoparticles, cytotoxic agents, and biology of tumors, CytImmune is developing a pipeline of proprietary drug candidates by binding potent anti-cancer agents - whose toxicity profiles currently prevent or severely limit clinical use - to its patented tumor-targeting platform nanotechnology. The company's nanomedicine technology is highly versatile and may be used with a broad spectrum of anti-cancer agents. *

	Start	1988-01-01 established
	Industry	cancer drug
	Industry 2	nanotechnology

	Region	Rockville, MD
	Country	United States (USA)
	Street	15010 Broschart Road Suite 270
	City	20850 Rockville, MD
	Tel	+1-301-825-3041
		Address record changed: 2020-12-02

Basic data	Employees	n. a.

		* Document for »About Section«:

		Record changed: 2023-07-10

Picture EBD Group BIO-Europe 2026 Köln Cologne to 31 Jul 650x200px

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to [email protected] and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]